STOCK TITAN

[SCHEDULE 13G] iTeos Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages used herein are calculated based upon 38,273,795 shares of common stock outstanding as of April 22, 2025, as reported by the Company in its Quarterly Report on Form 10-Q filed with the SEC on April 28, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages used herein are calculated based upon 38,273,795 shares of common stock outstanding as of April 22, 2025, as reported by the Company in its Quarterly Report on Form 10-Q filed with the SEC on April 28, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages used herein are calculated based upon 38,273,795 shares of common stock outstanding as of April 22, 2025, as reported by the Company in its Quarterly Report on Form 10-Q filed with the SEC on April 28, 2025.


SCHEDULE 13G



Ridgeback Capital Investments L.P.
Signature:/s/ Nicole Venezia
Name/Title:Nicole Venezia/General Counsel
Date:07/25/2025
Ridgeback Capital Investments LLC
Signature:/s/ Nicole Venezia
Name/Title:Nicole Venezia/General Counsel
Date:07/25/2025
Ridgeback Capital Management LLC
Signature:/s/ Nicole Venezia
Name/Title:Nicole Venezia/General Counsel
Date:07/25/2025
Exhibit Information

Exhibit Number 99.1 - Joint Filing Agreement